A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.
PHASE3CompletedINTERVENTIONAL
Enrollment
130
Participants
Timeline
Start Date
Not specified
Study Completion Date
November 30, 2005
Conditions
Cytomegalovirus Infections
Interventions
DRUG
ganciclovir
Trial Locations (1)
35294
NIAID/DMID/CASG Central Unit, Birmingham
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)